Oncology
Rheumatology
Neurology
Other Products
Ibrutinib
Ibrutinib is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), waldenstrom’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.